Impact of U.S. Preventive Services Task Force lung cancer screening update on drivers of disparities in screening eligibility
Cancer Medicine · 2023-02 · 12 (4) · 4647-4654
DOI: 10.1002/cam4.5066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 24.07.2022. Verfasst von Kristin G Maki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, National Cancer Institute.
Abstract (Originalsprache)
Background
In 2021, the U.S. Preventive Services Task Force (USPSTF) updated its recommendation to expand lung cancer screening (LCS) eligibility and mitigate disparities. Although this increased the number of non‐White individuals who are eligible for LCS, the update's impact on drivers of disparities is less clear. This analysis focuses on racial disparities among Black individuals because members of this group disproportionately share late‐stage lung cancer diagnoses, despite typically having a lower intensity smoking history compared to non‐Hispanic White individuals.
Methods
We used data from the National Health Interview Survey to examine the impact of the 2021 eligibility criteria on racial disparities by factors such as education, poverty, employment history, and insurance status. We also examined preventive care use and reasons for delaying medical care.
Results
When comparing Black individuals and non‐Hispanic White individuals, our analyses show significant differences in who would be eligible for LCS: Those who do not have a high school diploma (28.7% vs. 17.0%, p = 0.002), are in poverty (26.2% vs. 14.9%, p < 0.001), and have not worked in the past 12 months (66.5% vs. 53.9%, p = 0.009). Further, our analyses also show that more Black individuals delayed medical care due to not having transportation (11.1% vs. 3.6%, p < 0.001) compared to non‐Hispanic White individuals.
Conclusions
Our results suggest that despite increasing the number of Black individuals who are eligible for LCS, the 2021 USPSTF recommendation highlights ongoing socioeconomic disparities that need to be addressed to ensure equitable access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Data Science, University of Mississippi Medical Center, Jackson, Mississippi, USA.
- Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Kristin G Maki, Iakovos Toumazis, Sanjay Shete, Robert J Volk
Förderung
- NCI NIH HHS
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Maki, K. G., Talluri, R., Toumazis, I., Shete, S., & Volk, R. J. (2023). Impact of U.S. Preventive Services Task Force lung cancer screening update on drivers of disparities in screening eligibility. Cancer Medicine, 12(4), 4647-4654. https://doi.org/10.1002/cam4.5066
Vancouver
Maki KG, Talluri R, Toumazis I, Shete S, Volk RJ. Impact of U.S. Preventive Services Task Force lung cancer screening update on drivers of disparities in screening eligibility. Cancer Medicine. 2023;12(4):4647-4654. doi:10.1002/cam4.5066
BibTeX
@article{Maki2023,
author = {Maki, Kristin G and Talluri, Rajesh and Toumazis, Iakovos and Shete, Sanjay and Volk, Robert J},
title = {Impact of U.S. Preventive Services Task Force lung cancer screening update on drivers of disparities in screening eligibility},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {4},
pages = {4647--4654},
doi = {10.1002/cam4.5066}
}
EUVIMED